Physician profile
David Tay
NPI 1962440263
$6,228.71
in general payments reported to CMS, 2019-2025
23 companies · $668 in 2025
The $668 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $512 · 2021: $686 · 2022: $1,389 · 2023: $1,038 · 2024: $1,070 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,576 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.21 |
| Education | $200.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,139.02 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $1,027.40 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $844.67 | 2019-2025 | Tavneos, Parsabiv, Krystexxa |
| Opko Pharmaceuticals, LLC | $563.41 | 2020-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $442.92 | 2022-2025 | |
| Horizon Therapeutics Plc | $313.42 | 2021-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $266.99 | 2019-2021 | |
| Vifor Pharma, INC. | $209.87 | 2019-2023 | Korsuva, Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.40 | 2022-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $191.97 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $189.04 | 2022-2023 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $179.39 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $118.40 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $96.92 | 2019 | |
| Boston Scientific Corporation | $92.89 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $69.38 | 2023-2024 | Lupkynis |
| Ardelyx, INC. | $65.86 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $63.36 | 2024-2025 | Acthar |
| Lilly USA, LLC | $55.09 | 2024 | Jardiance |
| Arbor Pharmaceuticals, INC. | $38.56 | 2019 | |
| Daiichi Sankyo INC. | $19.73 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.46 | 2024 | Keveyis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.